Table 1.
Clinical and causality characteristics of cefazolin induced liver injury (n = 19)
| Feature | No (%) |
|---|---|
| Age (median-years) | 53 |
| Female | 8 (42%) |
| BMI (median-kg/m2) | 26 |
| Prior history of any drug allergy | 9 (47) |
| Heavy alcohol use* | 12 (63) |
| Diabetes mellitus | 5 (26) |
| Hepatitis C (HCV RNA positive) | 1 (5) |
| Time from administration to symptom onset | |
| < 1 week | 3 (16) |
| 2–4 weeks | 13 (68) |
| > 4 weeks | 3 (16) |
| Time to first laboratory abnormality | |
| < 1 week | 1 |
| 1–2 weeks | 5 |
| 3–4 weeks | 13 |
| Jaundice | 18 (95) |
| Itching | 19 (100) |
| Nausea | 15 (79) |
| Abdominal pain | 5 (26) |
| Rash | 6 (32) |
| Fever | 9 (47) |
| Eosinophilia | 5 (26) |
| Hospitalization | 11(69) |
| Severity | |
| Mild | 1 (5) |
| Moderate | 6 (32) |
| Moderate & hospitalized | 10 (53) |
| Severe | 2 (11) |
| Fatal | 0 |
| Causality | |
| Probable | 1(5) |
| Highly likely | 16 (84) |
| Definite | 2 (11) |
| Persistent abnormal liver tests more than 6 months | 3 (16) |
BMI, body mass index
*
>2 drinks/day in men and >1 drink/day women